Hilleman Laboratories Singapore Accelerates Innovation with SAP

Company looks to advance vaccine research and development for global health impact

Singapore November 3, 2021 SAP SE (NYSE: SAP) today announced that Hilleman Laboratories Singapore Pte. Ltd. (Hilleman Labs), a global biopharmaceutical company, has selected RISE with SAP to digitalise and accelerate innovation in its vaccine development programmes.

Hilleman Labs conducts research to develop cost-effective vaccines that tackle prevalent yet highly preventable diseases such as rotavirus, cholera, and shigella, in low and middle income countries. To achieve this, it is critical for the company to harness technological innovations to enhance collaboration between stakeholders, gather useful insights from multiple data sources, and accelerate the vaccine development process while ensuring industry compliance.

RISE with SAP, SAP’s new Business Transformation as a Service (BTaaS) is a solution that supports customers in identifying value creation potential in the planning of strategic IT projects.

Hilleman Labs’ adoption of RISE with SAP is aimed at enabling it to deploy a flexible digital infrastructure that complements, extends, and integrates with other solutions. New technologies such as artificial intelligence, machine learning and advanced analytics capabilities have been embedded into the system. The objective is to enable scientists to conduct real-time analysis of process development and analytics, clinical and genomics data from different sources as well as create patient cohorts and check local feasibility of clinical trials quickly. The new solution is also intended to promote collaboration and provides access to the world’s largest business network – including SAP’s supplier, logistics, and asset intelligence networks.

VIDEO: Discover how RISE with SAP can help businesses transform with fast time to value on their way to becoming an Intelligent Enterprise

The new infrastructure is targeted at achieving faster time to value and improved savings, speed, and decisions across the company by breaking down silos and integrating data, intelligent technology and Enterprise Resource Planning (ERP) software on a single platform and data model. The deployment was achieved within a short timeframe of 75 days, supported by SAP partner ABEAM Consulting Singapore, engaged by Hilleman Labs as its implementation partner.

“Infectious diseases while highly prevalent globally are preventable by vaccination, which underscores the importance of investing in research and development of vaccines that are equitable, affordable, and sustainable,” said Dr Raman Rao, Chief Executive Officer, Hilleman Labs. “With the adoption of RISE with SAP, our goal is to become more agile, innovative and productive as we accelerate our efforts to develop new vaccines and unlock new vaccine development methods that could have significant impact globally.”

“Amidst the rising needs of growing populations and the transition into the never normal, healthcare continues to be a critical yet underserved need, in part due to the complexity of developing and enabling cost-effective delivery at scale. By adopting a modern, innovative cloud solution such as RISE with SAP, Hilleman Labs has been able to embark on its mission to holistically transform into an intelligent enterprise and stay ahead of their industry,” said Eileen Chua, Managing Director, SAP Singapore.

“Their vaccine development efforts are now backed by a strong digital core that aims to offer greater visibility, efficiency and agility while achieving business outcomes and supporting their mission to improve global health,” added Chua.

In its Q3 earnings announcement, SAP has also highlighted a strong demand for RISE with SAP from companies of all sizes, and closed deals with more than 300 customers globally.

About Hilleman Laboratories
Hilleman Laboratories is a first-of-its-kind biopharmaceuticals company that focuses on the development of vaccines to fulfil unmet health needs in the developing world. The company centres its efforts on preventable diseases that are highly prevalent in developing countries such as rotavirus, cholera and shigellosis. It was formed in 2011 through an equal joint-venture partnership between Merck Sharp & Dohme Corp. (MSD), a global research-driven pharmaceutical company and Wellcome Trust, a global charitable foundation dedicated to human and animal health.

For more information, press only:
Darryn Lim, darryn.lim@sap.com
Omnicom PR Group for SAP, sng.sap.wg@omnicomprgroup.com
SAP Press Room; press@sap.com